Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Hold” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given an average rating of “Hold” by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $9.33.

Several equities analysts have recently weighed in on FULC shares. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Leerink Partners reissued a “market perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Finally, Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $4.48 on Thursday. Fulcrum Therapeutics has a one year low of $2.86 and a one year high of $13.70. The business has a fifty day moving average of $3.94 and a 200 day moving average of $5.55. The firm has a market capitalization of $241.65 million, a P/E ratio of -14.45 and a beta of 2.06.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of FULC. Barclays PLC grew its stake in Fulcrum Therapeutics by 367.1% during the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after acquiring an additional 97,565 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Fulcrum Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock worth $4,716,000 after buying an additional 13,485 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Fulcrum Therapeutics during the third quarter valued at approximately $254,000. State Street Corp lifted its stake in shares of Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after purchasing an additional 638,955 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Fulcrum Therapeutics in the 3rd quarter worth approximately $721,000. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.